Molina Healthcare

Global Experts from SEPA Call for the Control of Gingivitis Rather than Waiting for Periodontitis to Develop

Retrieved on: 
Monday, April 8, 2024
CASA, Toothpaste, Head, Confusion, Tooth brushing, EFP, Journal of Clinical Periodontology, Patient, Quality of life, Complutense University of Madrid, UCM, Therapy, Dental, Oral hygiene, Etiology, United States of Europe, Risk, Education, Gingivitis, Treatment, Recurrence, Dentistry, Prevalence, Disease, Clinical, White paper, Public, Knowledge, Research, University, Overalls, University College London, Mouthwash, Dentist, Molina Healthcare, Health, Motivation, Incidence, Physician, British Dental Journal, Inflammation, Pharmacist, Plaque, Systematic review, Bleeding, S3, Meta-analysis

SEPA: Limited knowledge among oral health teams of the recommendations and evidence currently available on oral antiseptics (that are clinically proven to be effective) reduces their implementation; therefore, more practical and simple advice is proposed.

Key Points: 
  • This was highlighted at an International Summit of Experts held at the Casa de las Encías in Madrid, Spain, the headquarters of the SEPA Foundation.
  • "Periodontal diseases are prevalent worldwide, affecting hundreds of millions of people," says the meeting coordinator, Dr. Paula Matesanz, vice president of SEPA.
  • As Dr. Iain Chapple summarizes, "It is time for a paradigm shift: we must control gingivitis and not wait until periodontitis develops."
  • J Clin Periodontol 2022 Jun:49 Suppl 24:4-71 (version adapted by SEPA available at https://portal.guiasalud.es/gpc/tratamiento-periodontitis-estadio-iv )
    * Chapple I, Time to take gum disease seriously.

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Retrieved on: 
Sunday, April 7, 2024
Uric acid, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, Atherosclerosis, FAHA, Cleveland Clinic, Bempedoic acid, Ezetimibe, Therapy, Anemia, Pain, MACE, Sinusitis, ACC, FOMA, FNLA, FACC, Obesity, Cardiovascular disease, Esperion Therapeutics, Abdominal pain, Risk, Gout, Spasm, Woman, American College, Body mass index, ESPR, Back pain, Outcome, ATP, Safety, Fatigue, Arthralgia, ANN, Angioedema, Kidney, Journal, Constipation, University, Adverse event, Pregnancy, CLEAR, Rash, MPH, Rupture, FDA, Molina Healthcare, JACC, Hypersensitivity, Health, Circulatory system, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Dietary supplement

ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with obesity. These results align with the American College of Cardiology’s robust diversity, equity and inclusion programs to drive cultural change across the profession and ensure that the cardiovascular care team is as diverse as the patients they care for and that all patients are represented in cardiovascular research. The data also reinforce the mission of the ACC: transforming cardiovascular care for all.

Key Points: 
  • “Bempedoic acid is the only FDA approved non-statin LDL lowering therapy to demonstrate reductions in MACE in both primary prevention and secondary prevention patient populations.
  • The Hispanic population is the largest ethnic minority in the U.S., yet is a population historically underrepresented in clinical trials.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

The Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients Across Southern California

Retrieved on: 
Thursday, April 4, 2024
Partnership, Patient, Molina Healthcare, Physician

Commencing July 1, 2024, TOI will offer its cancer care services to patients affiliated with Healthly’s medical groups and associated physicians across the region.

Key Points: 
  • Commencing July 1, 2024, TOI will offer its cancer care services to patients affiliated with Healthly’s medical groups and associated physicians across the region.
  • Leveraging TOI’s extensive network of oncology clinics and providers, this partnership aims to deliver convenient and comprehensive cancer care services to patients within the Healthly network.
  • “Navigating cancer is a multifaceted challenge, often representing one of the most trying periods in a patient’s life.
  • Through this strategic partnership, we aim to offer innovative care pathways, including access to clinical trials, to enhance patient access to cutting-edge drugs and treatments at reduced costs.”

Child Abuse and Sex Trafficking: What You Might Not Know

Retrieved on: 
Tuesday, April 2, 2024
Depression, Psychological abuse, Substance abuse, Abuse, Child abuse, Anxiety, Hope, Polaris, Molina Healthcare, DCF, Statistics, Physical abuse, Survivor, Social services, Ecosystem, Curriculum, NCMEC, Toy

This month serves as a powerful reminder that child abuse prevention is not a solitary effort.

Key Points: 
  • This month serves as a powerful reminder that child abuse prevention is not a solitary effort.
  • On a state level, the statistics for child abuse in Florida in 2023 show concerning trends with reported cases on the rise.
  • Child abuse and sex trafficking are closely related, with child sex trafficking being a form of child abuse that occurs when a child under 18 is advertised, solicited, or exploited through a commercial sex act.
  • It is crucial to raise awareness about these interconnected challenges during Child Abuse Awareness Month and recognize the shared vulnerabilities that contribute to these forms of exploitation.

Children’s Home Society of NC Recognizes Child Abuse Prevention Month

Retrieved on: 
Wednesday, March 27, 2024
Research, CHS, OBGYN, Growth, Child, Caregiver, Parent, Risk, Education, News, Hope, Molina Healthcare, Behavior, Ecosystem, Safety, Toy

Greensboro, NC, March 27, 2024 (GLOBE NEWSWIRE) -- Each April Children’s Home Society of NC (CHS) recognizes National Child Abuse Prevention Month to reinforce the importance of families and communities working together to prevent child abuse and neglect.

Key Points: 
  • Greensboro, NC, March 27, 2024 (GLOBE NEWSWIRE) -- Each April Children’s Home Society of NC (CHS) recognizes National Child Abuse Prevention Month to reinforce the importance of families and communities working together to prevent child abuse and neglect.
  • Protective factors are conditions or attributes of individuals, families, communities, or the larger society that mitigate risk and promote healthy development and wellbeing.
  • Child First provides in-home supports to families of young children to help promote healthy attachment and strong parenting skills.
  • Children's Home Society is dedicated to providing top-quality, evidence-based programs and services to children and families throughout North Carolina.

Pennsylvania Employees Benefit Trust Fund Board of Trustees Appoints New Executive Director

Retrieved on: 
Tuesday, April 9, 2024
Professional Services, Insurance, Finance, Union, Business, Trustee, Strategic planning, Molina Healthcare, Business development, MBA, Executive director, Pennsylvania State University, Carnegie Mellon University, Commonwealth, Management

The Board of Trustees of the Pennsylvania Employees Benefit Trust Fund (PEBTF) today announced the appointment of Don Clair to the position of Executive Director.

Key Points: 
  • The Board of Trustees of the Pennsylvania Employees Benefit Trust Fund (PEBTF) today announced the appointment of Don Clair to the position of Executive Director.
  • Clair has over 20 years of health care experience, including various leadership roles within health insurance companies.
  • The PEBTF, established in 1988, administers health care benefits to approximately 68,000 eligible Commonwealth of Pennsylvania employees and 65,000 retirees and their dependents.
  • The PEBTF is governed by a Board of Trustees comprised both of Commonwealth and Union representatives.

Jonas Nursing & AACN Announce a Call for Applications for the New Cohort of Doctoral Nursing Scholars

Retrieved on: 
Monday, April 8, 2024
Nursing, Education, Health, Hospitals, Other Education, University, Training, Health policy, Partnership, School nursing, AACN, History, Policy, Faculty, Mentorship, Student, Molina Healthcare, Curriculum, Rural health, Social change, Environmental Health (journal), Pediatrics, Teaching

Today, Jonas Nursing , a leading supporter of doctoral nursing education in the U.S., and the American Association of Colleges of Nursing (AACN) announce the launch of the eighth cohort of the Jonas Scholars program.

Key Points: 
  • Today, Jonas Nursing , a leading supporter of doctoral nursing education in the U.S., and the American Association of Colleges of Nursing (AACN) announce the launch of the eighth cohort of the Jonas Scholars program.
  • Under next-generation family leadership, Jonas Nursing will bolster this initiative with a redesigned curriculum focused on preparing future nursing faculty leaders through four key pillars: mentoring, leadership development, policy, and teaching.
  • Jonas Nursing is the signature impact area of Jonas Philanthropies, whose other impact areas include Vision Health, Children’s Environmental Health, and Nature-Based Climate Solutions.
  • For more details about the Jonas Scholars program, visit AACN’s website or contact Noah Brown, Jonas Grant Manager, at [email protected] .

Global Wearable Technology in Healthcare Market Analysis 2024-2029: AI-powered Medical Wearables and Epidermal Technology Emerging a Key Trends - ResearchAndMarkets.com

Retrieved on: 
Monday, April 8, 2024
Technology, Wearables, Mobile Technology, Momentum, Garmin, Health, Patient, Conditional sentence, Artificial intelligence, Miniaturization, Sennheiser, RPM, Ageing, Lilium, Application, Vital signs, Data analysis, Diabetes, Heart rate, Thermoregulation, Heart failure, Pain management, Polar Electro, Market, Privacy, Medicine, PPG, Blood pressure, Sound, Molina Healthcare, Prevalence, Pharmacy, Computer security, Research, AI, Distribution, Polar, Robotics, Preventive healthcare, Machine learning, Consumer, Temperature, Growth, Remote patient monitoring, Environment, COVID-19, Traction, Government, Rehabilitation, Medical device

The global wearable technology in healthcare market value in 2023 stood at US$42.6 billion, and is likely to reach US$169 billion by 2029.

Key Points: 
  • The global wearable technology in healthcare market value in 2023 stood at US$42.6 billion, and is likely to reach US$169 billion by 2029.
  • The global wearable technology in healthcare market value is projected to grow at a CAGR of 25.82%, during the forecast period of 2024-2029.
  • By Application: According to the report, the global wearable technology in healthcare market is bifurcated into three applications: home healthcare, sports fitness and remote patient monitoring.
  • AI-powered Medical Wearables: Integration of artificial intelligence (AI) in medical wearables enhances data analysis and insights, improving diagnostic accuracy and personalized healthcare delivery.

Mobius Mobility & ABLE NH Call for Reassessment of Outdated and Harmful Medicare Reimbursement Policy

Retrieved on: 
Friday, April 5, 2024
Mobius, Employment, Disability, Organization, CE, Wheelchair, Health equity, Education, Public policy, Policy, Sale, Social isolation, Interview, MAE, Molina Healthcare, ABLE, Recreation, PMD, Multimedia, Medicare, FDA, CMS, Snow, Loneliness, Health insurance

MANCHESTER, N.H., April 5, 2024 /PRNewswire/ -- New Hampshire based organizations Mobius Mobility and ABLE NH are partnering together to urge the Centers for Medicare and Medicaid Services ("CMS") to update a harmful and outdated coverage policy. Disability advocacy group ABLE NH and iBOT® power wheelchair manufacturer Mobius Mobility call upon CMS to review its "in the home" limitation for coverage of mobility assistive equipment (MAE).

Key Points: 
  • MANCHESTER, N.H., April 5, 2024 /PRNewswire/ -- New Hampshire based organizations Mobius Mobility and ABLE NH are partnering together to urge the Centers for Medicare and Medicaid Services ("CMS") to update a harmful and outdated coverage policy.
  • Disability advocacy group ABLE NH and iBOT® power wheelchair manufacturer Mobius Mobility call upon CMS to review its "in the home" limitation for coverage of mobility assistive equipment (MAE).
  • ABLE NH, a disability justice organization serving New Hampshire, stands together with Mobius Mobility on this effort for CMS to reevaluate its coverage policy.
  • "While this bureaucratic status quo has persisted for far too long, Mobius Mobility and ABLE NH continue to push for meaningful progress," Lucas Merrow, CEO of Mobius Mobility said.

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Retrieved on: 
Friday, March 22, 2024
Glucose, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, European Medicines Agency, Ezetimibe, Therapy, Anemia, Pain, Sinusitis, Esperion Therapeutics, Bempedoic acid, Abdominal pain, Risk, Gout, Committee, Spasm, ESPR, Back pain, ATP, Safety, Membrane protein, Fatigue, CHMP, Arthralgia, Angioedema, Cardiovascular disease, Kidney, Constipation, Death, Adverse event, Pregnancy, CLEAR, Rash, Esperies, Rupture, FDA, Molina Healthcare, Hypersensitivity, Health, Conference, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Uric acid, Pharmaceutical industry

In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.

Key Points: 
  • In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.
  • They also include new indications for primary hyperlipidemia, alone or in combination with a statin, and are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.
  • NEXLETOL and NEXLIZET are also the first oral non-statin LDL-C lowering drugs to be approved by the FDA to reduce the risk of CV events in both primary and secondary prevention patients.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.